Nasdaq · CIK 0001583648
PVLA PALVELLA THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing 24 d ago. Close $138.77 on Oct 9, 2026, +99% from the 52-week low and -12% from the high.
Last 90 days
Net insider value
-$4.9M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$4.9M by 3 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
PVLAOct 9, 2026 · close 138.77
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at PALVELLA THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Kathleen Goin Chief Operating Officer sell | $655k 4,302 shares | -100% | - | |
| 40Moderate | George M Jenkins director sell | $4.2M 27,500 shares | -15% | - | |
| 42Moderate | Christopher P Kiritsy director sell | $49k 313 shares | -56% | - | |
| 29Weak | George M Jenkins director buy | $101k 4,990 shares | +3% | +85% from low-25% from high | |
| 22Weak | George M Jenkins director buy | $52k 4,000 shares | +2% | - | |
| 23Weak | James A Geraghty director buy | $1 1 shares | - | - |
Transactions
The last 44 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | MOption exercise Common Stock10b5-1 | +2,154 | $7.14 | $15k | 2,154 | 24 d ago |
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | MOption exercise Common Stock10b5-1 | +2,148 | $9.08 | $20k | 4,302 | 24 d ago |
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -1,659 | $151.16 | $251k | 2,643 | 24 d ago |
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -989 | $152.36 | $151k | 1,654 | 24 d ago |
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -1,654 | $153.24 | $253k | 0 | 24 d ago |
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,154 | $0.00 | $0 | 2,165 | 24 d ago |
| Sep 16, 2026 | Kathleen Goin Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,148 | $0.00 | $0 | 2,148 | 24 d ago |
| Sep 11, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -6,520 | $150.62 | $982k | 181,096 | 27 d ago |
| Sep 11, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -4,577 | $151.72 | $694k | 176,519 | 27 d ago |
| Sep 11, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -1,274 | $153.06 | $195k | 175,245 | 27 d ago |
| Sep 14, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -5,632 | $151.46 | $853k | 169,613 | 27 d ago |
| Sep 14, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -6,160 | $152.12 | $937k | 163,453 | 27 d ago |
| Sep 14, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -1,560 | $153.10 | $239k | 161,893 | 27 d ago |
| Sep 15, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -954 | $149.38 | $143k | 160,939 | 27 d ago |
| Sep 15, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -263 | $150.40 | $40k | 160,676 | 27 d ago |
| Sep 15, 2026 | George M Jenkins director | SOpen-market sale Common Stock10b5-1 | -560 | $151.33 | $85k | 160,116 | 27 d ago |
| Sep 2, 2026 | Christopher P Kiritsy director | MOption exercise Common Stock | +313 | $127.20 | $40k | 563 | 38 d ago |
| Sep 2, 2026 | Christopher P Kiritsy director | SOpen-market sale Common Stock | -313 | $157.00 | $49k | 250 | 38 d ago |
| Sep 2, 2026 | Christopher P Kiritsy director | MOption exercise Stock Option (Right to Buy)derivative | -313 | $0.00 | $0 | 0 | 38 d ago |
| Jun 10, 2025 | Tadd S. Wessel director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,350 | $0.00 | $0 | 12,350 | Jun 11, 2025 |
| Jun 10, 2025 | Christopher P Kiritsy director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,350 | $0.00 | $0 | 12,350 | Jun 11, 2025 |
| Jun 10, 2025 | Elaine J Heron director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,350 | $0.00 | $0 | 12,350 | Jun 11, 2025 |
| Jun 10, 2025 | Todd C Davis director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,350 | $0.00 | $0 | 12,350 | Jun 11, 2025 |
| Jun 10, 2025 | George M Jenkins director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,350 | $0.00 | $0 | 12,350 | Jun 11, 2025 |
| May 27, 2025 | Ashley Hartmann Kline Chief Commercial Officer | AGrant or award Incentive Stock Option (right to buy)derivative | +17,436 | $0.00 | $0 | 17,436 | Jun 3, 2025 |
| May 27, 2025 | Ashley Hartmann Kline Chief Commercial Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +111,496 | $0.00 | $0 | 111,496 | Jun 3, 2025 |
| Apr 9, 2025 | George M Jenkins director | POpen-market purchase Common Stock | +2,500 | $20.13 | $50k | 183,171 | Apr 10, 2025 |
| Apr 9, 2025 | George M Jenkins director | POpen-market purchase Common Stockindirect: by foundation | +2,490 | $20.27 | $50k | 13,516 | Apr 10, 2025 |
| Dec 18, 2024 | George M Jenkins director | POpen-market purchase Common Stock | +4,000 | $12.93 | $52k | 180,671 | Dec 19, 2024 |
| Dec 13, 2024 | Todd C Davis director | AGrant or award Stock Option (right to buy)derivative | +24,700 | $0.00 | $0 | 24,700 | Dec 17, 2024 |
| Dec 13, 2024 | Tadd S. Wessel director | AGrant or award Stock Option (right to buy)derivative | +24,700 | $0.00 | $0 | 24,700 | Dec 17, 2024 |
| Dec 13, 2024 | Jeffrey S Martini Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +126,416 | $0.00 | $0 | 126,416 | Dec 17, 2024 |
| Dec 13, 2024 | Matthew E Korenberg CFO, Treasurer | AGrant or award Stock Option (right to buy)derivative | +167,100 | $0.00 | $0 | 167,100 | Dec 17, 2024 |
| Dec 13, 2024 | Wes Kaupinen President and CEO | AGrant or award Stock Option (right to buy)derivative | +417,806 | $0.00 | $0 | 417,806 | Dec 17, 2024 |
| Dec 13, 2024 | Christopher P Kiritsy director | AGrant or award Stock Option (right to buy)derivative | +24,700 | $0.00 | $0 | 24,700 | Dec 17, 2024 |
| Dec 13, 2024 | George M Jenkins director | AGrant or award Stock Option (right to buy)derivative | +24,700 | $0.00 | $0 | 24,700 | Dec 17, 2024 |
| Dec 13, 2024 | Elaine J Heron director | AGrant or award Stock Option (right to buy)derivative | +24,700 | $0.00 | $0 | 24,700 | Dec 17, 2024 |
| Dec 13, 2024 | Kathleen Goin Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +27,843 | $0.00 | $0 | 27,843 | Dec 17, 2024 |
| Dec 13, 2024 | Bvf Partners L P/il other | JOther Common Stock, $0.001 par value | +234,323 | - | - | 371,916 | Dec 17, 2024 |
| Dec 13, 2024 | Bvf Partners L P/il other | JOther Common Stock, $0.001 par value | +174,958 | - | - | 282,223 | Dec 17, 2024 |
| Dec 13, 2024 | Bvf Partners L P/il other | JOther Common Stock, $0.001 par value | +29,648 | - | - | 38,961 | Dec 17, 2024 |
| Dec 12, 2024 | James A Geraghty director | DDisposition to issuer Series F Preferred Stock, par value $0.001 per share | -1 | $0.01 | $0 | 0 | Dec 12, 2024 |
| Dec 2, 2024 | Christopher P Kiritsy director | AGrant or award Stock Option (right to buy)derivative | +500 | $0.00 | $0 | 500 | Dec 9, 2024 |
| Aug 7, 2024 | James A Geraghty director | POpen-market purchase Series F Preferred Stock, par value $0.001 per share | +1 | $1.00 | $1 | 1 | Oct 28, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bvf Partners L P/ilother, owner, director
- Todd C Davisdirector, ceo, officer, owner
- James A Geraghtydirector
- Kathleen GoinChief Operating Officer
- Elaine J Herondirector
- George M Jenkinsdirector
- Christopher P Kiritsydirector
- Wes KaupinenPresident and CEO
- Ashley Hartmann KlineChief Commercial Officer
- Matthew E KorenbergCFO, Treasurer
- Jeffrey S MartiniChief Scientific Officer
- Tadd S. Wesseldirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.